About Orca Bio
Orca Bio is a company based in Menlo Park (United States) founded in 2016 by Jeroen Bekaert and Ivan Dimov. Orca Bio has raised $442 million across 2 funding rounds from investors including Kaiser Permanente, Lightspeed Venture Partners and Mubadala. The company has 66 employees as of December 31, 2021. Orca Bio offers products and services including Orca-T and Orca-Q. Orca Bio operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
- Headquarter Menlo Park, United States
- Employees 66 as on 31 Dec, 2021
- Founders Jeroen Bekaert, Ivan Dimov
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$442 M (USD)
in 2 rounds
-
Latest Funding Round
$250 M (USD), Series F
Jan 09, 2026
-
Investors
Kaiser Permanente
& 6 more
-
Employee Count
66
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orca Bio
Orca Bio offers a comprehensive portfolio of products and services, including Orca-T and Orca-Q.
Investigational therapy targeting cancer with high-precision T-cells
Investigational therapy for autoimmune diseases using advanced cells
People of Orca Bio
Unlock access to complete
Unlock access to complete
Software Development Team
18 people
Product Management Team
8 people
Advisor Team
7 people
Manufacturing Team
7 people
Leadership Team
6 people
Operations Team
5 people
Data Analysis and Operations Team
5 people
Human Resources and Administration
4 people
Unlock access to complete
Funding Insights of Orca Bio
Orca Bio has successfully raised a total of $442M across 2 strategic funding rounds. The most recent funding activity was a Series F round of $250 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orca Bio
Orca Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Kaiser Permanente, Lightspeed Venture Partners and Mubadala.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in technology, life sciences, and related sectors.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Orca Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orca Bio
Investment portfolio details for Orca Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Orca Bio
Detailed financials for Orca Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orca Bio Comparisons
Peer comparison for Orca Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orca Bio
Orca Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Therapeutics for autoimmune diseases are developed by the company.
|
Detailed competitors of Orca Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orca Bio
Complete news archive for Orca Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orca Bio
Orca Bio was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Orca Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Ivan Dimov is the current CEO of Orca Bio. They have also founded this company.
Orca Bio is a funded company, having raised a total of $442M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Orca Bio is 66.
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patients new immune system.
Orca Bio's top competitors include Moderna, argenx and Forge Biologics.
Orca Bio offers Orca-T and Orca-Q.
Orca Bio has 7 investors. Key investors include Kaiser Permanente, Lightspeed Venture Partners, Mubadala, 8VC, and DCVC.